Expert Interview
A Second Look: Discussing the potential of Incyte's mutCALR-targeted mAb, INCA033989, in patients with Essential Thrombocytopenia and Myelofibrosis
Ticker(s): INCYInstitution: Mount Sinai
- Assistant Professor at the Mount Sinai Health System (Icahn School of Medicine).
- Manages 40-50 patients with MF currently and is familiar with the MOMENTUM trial.
- Research interests include myeloproliferative neoplasms, especially polycythemia vera and myelofibrosis, as well as acute myeloid leukemia, hemophagocytic lymphohistiocytosis, systemic mastocytosis, and chronic myelomonocytic leukemia and has published extensively on these topics.
Where do you see the unmet need in myelofibrosis and ET now?
Added By: wilson_adminIn your opinion how strong is the data on INCA033989?
Added By: wilson_adminWhat other promising MoA's are under development for MF/ET?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
